Southbay Pharma Research
- Research works
- 2 ▲ 166% vs 2013–17
- Citations
- 92 40.4 per fractional work
- Top-10% rate
- 19.7% record average 16.5%
- Open access
- 26% world 28%
Not ranked overall: Southbay Pharma Research is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Which research topics does Southbay Pharma Research publish most on?
By volume: Ubiquitin and proteasome pathways, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors and Renal cell carcinoma treatment.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Ubiquitin and proteasome pathways Molecular Biology 0 works
- 2 Chronic Lymphocytic Leukemia Research Genetics 0 works
- 3 Protein Degradation and Inhibitors Molecular Biology 0 works
- 4 Renal cell carcinoma treatment Pulmonary and Respiratory Medicine 0 works
- 5 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 0 works
- 6 Cancer Genomics and Diagnostics Cancer Research 0 works
- 7 Antimicrobial Resistance in Staphylococcus Infectious Diseases 0 works
- 8 Streptococcal Infections and Treatments Public Health, Environmental and Occupational Health 0 works
- 9 Antibiotic Use and Resistance Applied Microbiology and Biotechnology 0 works
- 10 HER2/EGFR in Cancer Research Oncology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Southbay Pharma Research's research output changed?
Output in 2018–2022 was 166% higher than in 2013–2017.
Other research institutions in Buena Park
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.